A retail investor lays out a bullish medium-term case for small-cap pharma Catalyst Pharmaceuticals based on strong financials, growth, low P/E and the newly approved AGAMREE drug, while flagging litigation and niche-market risks.
CPRX — LONG The author owns a sizable position in Catalyst Pharmaceuticals and likes it as a medium-term hold, citing high cash with no debt enabling buybacks, high gross/net margins, strong YoY revenue growth (492M in 2024, ~565-585M in 2025), a low ~13 P/E, and ROE/ROIC/ROA of 35-38%/35-36%/22-23%. The newly approved drug AGAMREE is a growth catalyst. Main stated risks are that the core drug Firdapse faces lawsuits and FDA issues, revenue is capped by very niche drugs, and as a small-cap pharma it is subject to investor sentiment.
great financial; in particular high cash and no debt allowing share buyback in case of any major dips, high gross and net margins
This Reddit post, published January 20, 2026, features u/Ultpanchu discussing CPRX. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Ultpanchu · Tickers: CPRX